GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AIM ImmunoTech Inc (STU:HXB2) » Definitions » Additional Paid-In Capital

AIM ImmunoTech (STU:HXB2) Additional Paid-In Capital : €385.86 Mil(As of Mar. 2024)


View and export this data going back to . Start your Free Trial

What is AIM ImmunoTech Additional Paid-In Capital?


AIM ImmunoTech's quarterly additional paid-in capital declined from Sep. 2023 (€392.41 Mil) to Dec. 2023 (€384.23 Mil) but then increased from Dec. 2023 (€384.23 Mil) to Mar. 2024 (€385.86 Mil).

AIM ImmunoTech's annual additional paid-in capital increased from Dec. 2021 (€369.24 Mil) to Dec. 2022 (€394.85 Mil) but then declined from Dec. 2022 (€394.85 Mil) to Dec. 2023 (€384.23 Mil).

AIM ImmunoTech Additional Paid-In Capital Historical Data

The historical data trend for AIM ImmunoTech's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AIM ImmunoTech Additional Paid-In Capital Chart

AIM ImmunoTech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 306.21 330.89 369.24 394.85 384.23

AIM ImmunoTech Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 390.84 386.29 392.41 384.23 385.86

AIM ImmunoTech Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

AIM ImmunoTech Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of AIM ImmunoTech's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

AIM ImmunoTech (STU:HXB2) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AIM ImmunoTech Inc (STU:HXB2) » Definitions » Additional Paid-In Capital
Comparable Companies
SYBX LSTA NRXS NRSN TCRT BIOR BIXT LUMO ZIVO CNTX OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB XBRU:ARGX BNTX
Traded in Other Exchanges
AIM:USA HXB2:Germany
Address
2117 SW Highway 484, Ocala, FL, USA, 34473
Website
https://www.aimimmuno.com
AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders, viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases and drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer and triple negative metastatic breast cancer. The company is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.

AIM ImmunoTech (STU:HXB2) Headlines

No Headlines